Postexposure treatment with aminophylline protects against phosgene- induced acute lung injury

Experimental Lung Research

Volumn 23, Issue 4, 1997, Pages 317-332

  Sciuto, Alfred M ^a,e   Strickland, Paul T ^b   Kennedy, Thomas P ^a,d   Gurtner, Gail H ^c  

^a U States Army Med Res Inst C   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; PHOSGENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GAS EXCHANGE; LIPID PEROXIDATION; LUNG ARTERY PRESSURE; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RABBIT; SMOOTH MUSCLE RELAXATION;

EID: 0031005546     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149709039229     Document Type: Article

References (41)

1. Farrukh IS, Gurtner GH, Michael JR. Pharmacological modification of pulmonary vascular injury: possible role of cAMP. J Appl Physiol. 1987;62:47-54.
2. Mizus I, Summer W, Farrukh IS, Michael JR, Gurtner GH. Isoproterenol or aminophylline attenuate pulmonary edema after acid injury. Am Rev Respir Dis. 1985;131:256-259.
3. Spiers EM. Chemical Warfare. Urbana: University of Illinois Press; 1986.
4. Cucinell SA. Review of the toxicity of long-term phosgene exposure. Arch Environ Hlth. 1974;28: 272-275.
5. Diller WF. Medical phosgene problems and their possible solutions. J Occup Med. 1978;20:189-193.
6. Currie WD, Hatch GE, Frosolono MP. Pulmonary alterations in rats due to phosgene inhalation. Fund Appl Toxicol. 1987;8:107-114.
7. Daly de Burgh I, Eggleton P, Elsden SR, Hebb CO. Biochemical study of isolated perfused lungs with special reference to the effects of phosgene. QJ Exp Physiol. 1946;33:215-240.
8. Diller WF, Brucht J, Dahnen W. Pulmonary changes in the rat following low phosgene exposures. Arch Toxicol. 1985;57:184-190.
9. Laqueur E, Magnus R. Uber kampfgasvergiftungen, III: experimentelle pathologie der phosgenvergiftung. Zschr ges Exp Med. 1921;13:200-290.
10. Pawlowski R, Frosolono MP. Effects of phosgene on rat lungs after a single high-level exposure, II: ultrastructural alterations. Arch Environ Hlth. 1977;32:278-283.
11. Potts AM, Simon FP, Gerard RW. The mechanisms of phosgene and diphosgene. Arch Biochem. 1949;24:329-337.
12. Babad H, Zeiler AG. The chemistry of phosgene. Chem Rev. 1973;73:75-91.
13. Frosolono MP, Pawlowski R. Effect of phosgene on rat lungs after single high-level exposure; I: biochemical alterations. Arch Environ Hlth. 1977;32:271-277.
14. Sciuto AM, Stotts RR, Chittenden V, Choung E, Heflin MD. Changes in absorbance at 413 nm in plasma from three rodent species exposed to phosgene. Biochem Biophys Res Commun. 1996;226: 906-911.
15. Guo Y-L, Kennedy TP, Michael JR, et al. Mechanisms of phosgene-induced toxicity: role of arachidonate mediators. J Appl Physiol. 1990;69:1615-1622.
16. Kennedy TP, Michael JR, Hoidal JR, et al. Dibutyryl cAMP, aminophylline, and β-adrenergic agonist protect against pulmonary edema caused by phosgene. J Appl Physiol. 1989;67:2542-2552.
17. Sciuto AM, Strickland PT, Kennedy TP, Guo Y-L, Gurtner GH. Intratracheal administration of dibutyryl cAMP attenuates edema formation in phosgene-induced acute lung injury. J Appl Physiol. 1996;80:149-157.
18. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. Protective effects of N-acetylcysteine treatment of phosgene exposure in rabbits. Am J Respir Crit Care Med. 1995;151:768-772.
19. Rhinehart RH, Hatch T. Concentration-time product (CT) as an expression of dose in sublethal exposure to phosgene. Am Ind Hyg Assoc J. 1964;25:545-553.
20. Guo Y-L. A Study of the Mechanism of Phosgene-Induced Lung Injury: The Role of Arachidonate Mediators. Thesis, Johns Hopkins University; 1987.
21. 4 increases pulmonary vascular permeability and pressure by different mechanisms. Am Rev Respir Dis. 1986;134:229-232.
22. Hayes EC, Lombardo D, Girard Y, et al. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol. 1983;13:429-433.
23. Peters SE, Schulman E, Liu M, Hayes E, Lichtenstein L. Separation of major prostaglandins, leukotrienes and monoHETEs by high performance liquid chromatography. J Immunol. 1983;64:335-343.
24. Tietze P. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem. 1969;27:502-522.
25. Buege J, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;51:302-310.
26. Lowry O, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem. 1951;193:265-275.
27. Duncan DB. Multiple range tests for correlated and heteroscedastic means. Biometrics. 1957;13: 164-176.
28. Zar TH. Biostatistical Analysis, 2d ed. Englewood Cliffs, NJ: Prentice Hall; 1984.
29. Hitchcock M. Adenosine 3′-5′-cyclic monophosphate phosphodiesterase in guinea pig lung: properties and effects of adrenergic drugs. Biochem Pharmacol. 1969;22:959-969.
30. Gurtner GH, Sciuto AM, Knoblauch A. The Role of cAMP in the regulation of pulmonary vascular permeability. In: Johnson A, Ferro T, eds. Lung Vascular Injury: Molecular and Cellular Response, Vol 60. New York: Dekker; 1992: 99-111.
31. Foy T, Marion J, Brigham K, Harris TR. Isoproterenol and aminophylline reduce lung capillary filtration during high permeability. J Appl Physiol: Respir Environ Exer Physiol 1979;46:146-151.
32. Sheldon R, Moy A, Lindsey K, Shasby S, Shasby DM. Role of myosin-light chain phosphorylation in endothelial cell retraction. Am J Physiol: Lung Cell Mol Physiol. 1994;9:L606-L612.
33. Trethewie ER. Pharmacology of phosgene. Med J Australia. 1947;20:612-618.
34. Keuhl FA, Zanetti ME, Soderman DD, Miller DK, Ham EA. Cyclic AMP-dependem regulation of lipid mediators in white cells. Am Rev Respir Dis. 1987;136:210-213.
35. Nielson CP, Crowley JJ, Morgan ME, Vestal RK. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3′-5′-adenosine monophosphate. Am Rev Respir Dis. 1987;137:25-30.
36. Singer, AL, Ariano MA. Localization of cyclic adenosine monophosphate phosphodiesterase in mouse alveolar cells. J Histochem Cytochem. 1981;29:1372-1376.
37. Erneux C, van Sande J, Mist F, Cochaux P, Decoster C, Dumont JE. A mechanism in the control of intracellular cAMP levels: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intracellular free calcium. Mol Cell Endocrinol. 1985;43:123-134.
38. Werrlein RJ, Kirby SD, Madren-Whalley J. Phosgene-induced calcium changes in pulmonary artery endothelial cells. In: Salem H, Katz S, eds. Advances in Animal Testing for Safety and Efficacy. Washington, DC: Taylor & Francis; in press.
39. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev. 1990;70:761-845.
40. Webb RC, Bohr DP. Relaxation of vascular smooth muscle by isoproterenol, dibutyryl cAMP, and theophylline. J Pharmacol Exp Therapeut. 1981;217:26-35.
41. Akerboom ME, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981;77:373-382.